Reference:
1. Reid BM, Permuth JB, Sellers TAJCb, medicine. Epidemiology of ovarian cancer: a review. 2017;14(1):9.
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. 2018;68(4):284-96.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal AJCacjfc. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2018;68(6):394-424.
4. Du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). 2005;16(suppl_8):viii7-viii12.
5. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019: Featured Updates to the NCCN Guidelines. 2019;17(8):896-909.
6. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. 2016;143(1):3-15.
7. Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, et al. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. 2004;94(1):161-6.
8. Dell’Anna T, Signorelli M, Benedetti-Panici P, Maggioni A, Fossati R, Fruscio R, et al. Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial. 2012;107(5):785-92.
9. Fagotti A, De Iaco P, Fanfani F, Vizzielli G, Perelli F, Pozzati F, et al. Systematic Pelvic and Aortic Lymphadenectomy in Advanced Ovarian Cancer Patients at the Time of Interval Debulking Surgery: A Double-Institution Case–Control Study. 2012;19(11):3522-7.
10. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. 2019;380(9):822-32.
11. Beesley V, Janda M, Eakin E, Obermair A, Battistutta DJC. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. 2007;109(12):2607-14.
12. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV. Cochrane Handbook for Systematic Reviews of Interventions. Available from: www.training.cochrane.org/handbook. .
13. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median , range , and the size of a sample. 2005;10:1–10. .
14. Song N, Gao YJIJoGC. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer. 2019;29(4):761-7.
15. Eoh KJ, Yoon JW, Lee I, Lee JY, Kim S, Kim SW, et al. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. 2017;116(3):329-36.
16. Eoh KJ, Lee J-Y, Yoon JW, Nam EJ, Kim S, Kim S-W, et al. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery. 2017;8(23):37807.
17. Salgado-Ceballos I, Ríos J, Pérez-Montiel D, Gallardo L, Barquet-Muñoz S, Salcedo-Hernández R, et al. Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience. 2017;41:1-5.
18. Paik ES, Shim M, Choi HJ, Lee Y-Y, Kim T-J, Lee J-W, et al. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. 2016;143(2):252-7.
19. Iwase H, Takada T, Iitsuka C, Nomura H, Abe A, Taniguchi T, et al. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients. 2015;26(4):303-10.
20. Schwartz L, Schrot-Sanyan S, Brigand C, Baldauf J-J, Wattiez A, Akladios CJAr. Impact of pelvic and para-aortic lymphadenectomy in advanced ovarian cancer after neoadjuvant chemotherapy. 2015;35(10):5503-9.
21. Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, et al. Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. 2013;18(6):1107-13.
22. Sakai K, Kajiyama H, Umezu T, Shibata K, Mizuno M, Suzuki S, et al. Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients? 2012;38(7):1018-23.
23. Chang S-J, Bristow RE, Ryu H-SJGo. Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. 2012;126(3):381-6.
24. Abe A, Furumoto H, Irahara M, Ino H, Kamada M, Naka O, et al. The impact of systematic para‐aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer. 2010;36(5):1023-30.
25. Du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer JJJoco. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. 2010;28(10):1733-9.
26. Scarabelli C, Gallo A, Visentin M, Canzonieri V, Carbone A, Zarrelli AJIJoGC. Systematic pelvic and para‐aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease. 1997;7(1):18-26.
27. Scarabelli C, Gallo A, Zarrelli A, Visentin C, Campagnutta EJGo. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: potential benefit on survival. 1995;56(3):328-37.
28. Aletti GD, Dowdy S, Podratz KC, Cliby WAJAjoo, gynecology. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer. 2006;195(6):1862-8.
29. Ercelep O, Ozcelik M, Gumus MJCpic. Association of lymphadenectomy and survival in epithelial ovarian cancer. 2019;43(2):151-9.
30. Gmyrek LJ, Jonska-Gmyrek J, Sobiczewski P, Panek G, Bidzinski MJOl. Evaluation of intraoperative and postoperative complications related to lymphadenectomy in ovarian cancer patients. 2011;2(3):537-41.
31. Ho C-M, Chien T-Y, Shih B-Y, Huang S-HJGo. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. 2003;88(3):394-9.
32. Maggioni A, Panici PB, Dell’Anna T, Landoni F, Lissoni A, Pellegrino A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. 2006;95(6):699-704.
33. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. 2005;97(8):560-6.
34. Ho CM, Chien TY, Shih BY, Huang SH. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecologic oncology. 2003;88(3):394‐9.
35. Siegel R, Naishadham DJCCjC. jemal A: Cancer statistics, 2013. 2013;63:11-30.
36. Hunn J, Rodriguez GCJCo, gynecology. Ovarian cancer: etiology, risk factors, and epidemiology. 2012;55(1):3-23.
37. Trimbos B, Timmers P, Pecorelli S, Coens C, Ven K, Van der Burg M, et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. 2010;102(13):982-7.
38. Holschneider CH, Berek JS, editors. Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars in surgical oncology; 2000: Wiley Online Library.
39. Eisenkop SM, Spirtos NMJGo. The clinical significance of occult macroscopically positive retroperitoneal nodes in patients with epithelial ovarian cancer. 2001;82(1):143-9.
40. Morice P, Joulie F, Rey A, Atallah D, Camatte S, Pautier P, et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. 2004;25(2):169-74.
41. Berek JSJIJoGC. Lymph node-positive stage IIIC ovarian cancer: a separate entity? 2009;19(Suppl 2).
42. Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, et al. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. 2010;20(4).
43. Gao J, Yang X, Zhang YJJjoco. Systematic lymphadenectomy in the treatment of epithelial ovarian cancer: a meta-analysis of multiple epidemiology studies. 2015;45(1):49-60.
44. Zhou J, Shan G, Chen YJJjoco. The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. 2016;46(8):718-26.
45. Lin Q, Liu W, Xu S, Li J, Tong JJJoOR. The value of systematic lymphadenectomy during debulking surgery in the treatment of ovarian cancer: a meta-analysis of randomized controlled trials. 2020;13:1-8.
46. Xu D, Xue J, Rozan R, Li LJAopm. The role systematic lymphadenectomy plays in determining the survival outcome for advanced ovarian cancer patients: a meta-analysis. 2020.
47. Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang LJFio. Prognostic significance of systematic lymphadenectomy in patients with optimally debulked advanced ovarian cancer: a meta-analysis. 2020;10:86.
48. Qin M, Jin Y, Ma L, Zhang Y-Y, Pan L-YJO. The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies. 2018;9(9):8614.